10 facts about cilostazol therapy in cardiology Review article
Article Sidebar
Published:
Jun 30, 2018
Keywords:
intermittent claudication, arterial disease of the lower limbs, cilostazol
Main Article Content
Abstract
Cilostazol is indicated for the symptomatic treatment of intermittent claudication. Its effectiveness results from pleiotropic effects: vasodilatation, antiplatelet effect. Thanks to this, it affects the extension of the distance of intermittent claudication, which translates into an improvement in the quality of life among patients with arterial disease of the lower limbs. The article includes 10 facts that may help in the use of the drug in patients with co-existing cardiac problems.
Article Details
How to Cite
Balsam , P. (2018). 10 facts about cilostazol therapy in cardiology. Medycyna Faktow (J EBM), 11(2(39), 125-128. https://doi.org/10.24292/01.MF.0218.4
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. European Stroke Organisation, Tendera M., Aboyans V., Bartelink M.L. et al.; ESC Committee for Practice Guidelines: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur. Heart J. 2011; 32(22): 2851-2906.
2. Schmieder F.A., Comerota A.J.: Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am. J. Cardiol. 2001; 87(12A): 3D-13D.
3. Alonso-Coello P., Bellmunt S., McGorrian C. et al.: Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e669S-90S.
4. Writing Committee Members, Gerhard-Herman M.D., Gornik H.L., Barrett C. et al.: 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc. Med. 2017; 22(3): NP1-NP43.
5. Hiatt W.R., Money S.R., Brass E.P.: Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J. Vasc. Surg. 2008; 47(2): 330-336.
6. Thompson P.D., Zimet R., Forbes W.P., Zhang P.: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Card. 2002; 90(12): 1314-1319.
7. Bedenis R., Stewart M., Cleanthis M. et al.: Cilostazol for intermittent claudication. Cochrane Database Syst. Rev. 2014; 10: CD003748.
8. Oyama N., Yagita Y., Kawamura M. et al.: Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke 2011; 42(9): 2571-2577.
2. Schmieder F.A., Comerota A.J.: Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am. J. Cardiol. 2001; 87(12A): 3D-13D.
3. Alonso-Coello P., Bellmunt S., McGorrian C. et al.: Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e669S-90S.
4. Writing Committee Members, Gerhard-Herman M.D., Gornik H.L., Barrett C. et al.: 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc. Med. 2017; 22(3): NP1-NP43.
5. Hiatt W.R., Money S.R., Brass E.P.: Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J. Vasc. Surg. 2008; 47(2): 330-336.
6. Thompson P.D., Zimet R., Forbes W.P., Zhang P.: Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Card. 2002; 90(12): 1314-1319.
7. Bedenis R., Stewart M., Cleanthis M. et al.: Cilostazol for intermittent claudication. Cochrane Database Syst. Rev. 2014; 10: CD003748.
8. Oyama N., Yagita Y., Kawamura M. et al.: Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke 2011; 42(9): 2571-2577.